UNSPSC 41131718: Fetal hemoglobin assay

In this classification a fetal hemoglobin assay is a device that is used to determine the presence and distribution of fetal hemoglobin (hemoglobin F) in red cells or to measure the amount of fetal hemoglobin present. The assay may be used to detect fetal red cells in the maternal circulation or to detect the elevated levels of fetal hemoglobin exhibited in cases of hemoglobin abnormalities such as thalassemia (a hereditary hemolytic anemia characterized by a decreased synthesis of one or more types of hemoglobin polypeptide chains).

The hemoglobin determination may be made by methods such as electrophoresis, alkali denaturation, column chromatography, or radial immunodiffusion US FDA regulates Fetal hemoglobin assay under 21 CFR 864.7455 and under FDA product code KQI.

UNSPSC 41131718 Fetal hemoglobin assay is a Commodity code that in practice encompasses drug and substance testing supplies, laboratory consumables, and certified reference materials used by state and local public-health, criminal-justice, and occupational-health agencies for screening, confirmation, and forensic analysis of drug abuse and controlled substances. The code title does not reflect the actual scope of recent solicitations, which focus on immunoassay screening supplies, confirmatory testing reagents (LC/MS/MS, GC/MS), oral-fluid and hair-testing kits, urinalysis panels, drug standards for method validation, and naloxone—spanning clinical diagnostic work, offender monitoring, occupational health screening, and forensic laboratory operations. Issuing bodies include county community supervision departments, county health-care services and public-health units, municipal police and forensic laboratories, state forensic agencies, and universities. Collin County Community Supervision and Corrections Department in Texas and Collin County Health Care Services both appear as repeat buyers of testing-related services and supplies.

Recent activity spans Texas, Florida, Oregon, Georgia, North Carolina, and Wisconsin. The most concrete recent opportunity is Collin County Community Supervision and Corrections Department's RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, due July 23, 2026, requesting immunoassay screening with confirmatory LC/MS/MS or GC/MS, five- and six-panel drug screens, oral-fluid and hair testing, and SAMHSA or Texas DPS lab certification for approximately 25,031 annual tests across two sites, with an estimated contract value of $600,000 and a two-year initial term plus three optional one-year renewals. Pinellas County, Florida's Invitation to Quote 26-0305-ITQ (closed April 23, 2026) procured 131 line items of ISO/IEC 17025:2017-certified drug reference standards for forensic toxicology and seized-drug analysis, funded through the Paul Coverdell Forensic Sciences Improvement Act Program with approximately $49,034 in federal equipment and supplies dollars. Benton County, Oregon issued RFP SC0200300017156 for urinalysis testing services for its Family Treatment Court Program, due July 7, 2026, requiring CLIA certification, twice-weekly testing at minimum, broad drug panels with confirmatory testing, and secure web-based reporting within 48–72 hours. Gwinnett County, Georgia and the City of Charlotte, North Carolina are also actively soliciting drug testing supplies and services (RFP and drug/alcohol testing services respectively), though with limited scope detail in available sources.